New Opioid Battlefront: New York Charges Mallinckrodt With Insurance Fraud
The allegations (that Mallinckrodt misrepresented safety and efficacy) are similar to other suits but the insurance avenue provides another route to obtain financial remuneration.
You may also be interested in...
Despite the delay in a New York state opioid trial due to coronavirus, a motion has been filed to remove Mallinckrodt and SpecGx from proceedings. However, Nassau County opposed the motion.
Delays expected to have cascading effect beyond the current crisis; Federal Circuit to hear arguments remotely.
Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.